Wet Age Related Macular Degeneration

Wet AMD occurs when abnormal blood vessels grow under the retina and leak causing vision loss.

What is wet macular degeneration?

Wet macular degeneration occurs when abnormal blood vessels (known as choroidal neovascularization) grow under the macula. These new blood vessels may then bleed and leak fluid, causing the macula to bulge or lift up from its normally flat position, thus distorting or destroying central vision. It is called wet because of the fluid the leaks from the abnormal blood vessels. Patient with wet macular degeneration usually develop rapid vision loss over the course of weeks or months. Straight lines may look wavy because the macula is no longer smooth. Below is a discussion of various manifestations of wet AMD. Click the button to learn more about the treament of wet AMD

Treatment of Wet AMD

What is a Choroidal Neovascular membrane?

Choroidal neovascular membranes are new blood vessels that grow beneath the retina and disrupt vision. These blood vessels grow in an area called the choroid, the area between the retina and the sclera (the white part of your eye). The choroid supplies oxygen and nutrients to the eye. These blood vessel growths break through the barrier between the choroid and the retina. Although one would think that more blood vessels supplying nutrients to the eye would be good, it is not. The new blood vessels grow out with scarring. Also, they leak more than normal retinal blood vessels. Finally they can bleed and blood is very harmful to the retina. Rarely patient maintain good vision with choroidal neovascular membranes (about 10 or 20 percent). Most people lose central vision rapidly who develop choroidal neovascular membranes unless they are treated.

What is a Disciform Scar?

Untreated, a person with a choroidal neovascular membrane will usually develop a submacular scar like the one in the photo. The scars are white because the are composed mostly of fibroblasts. Subretinal scars cause degeneration of the overlying retina and loss of vision. The scars are circular or disc shaped and therefore are called disciform scars. They cause vision loss because they block the transport of nutrients from the supporting tissue under the retina (the retinal pigment epithelium) which is vital to the survival and function of the retina. Unfortunately, once the retina has been permanently damaged by a submacular scar it cannot be resurrected. Retinal tissue does not regenerate. It cannot be replaced. Research is being pursued all over the world trying to find a way to fix damaged retinas, but nothing, at the moment (January 2015) is close to being effective.

What is Subretinal Fluid?

A hallmark of wet AMD is subretinal fluid. This comes from leaking abnormal blood vessels under the macula. Their is not a firm attachment between the retina and the underlying retinal pigment epithelium. The retina is held in place against the underlying retinal pigment epithelium by a pump in the retinal pigment epithelium. This pump removes naturally occurring fluid in the subretinal space and keeps it dry. The leakage from a choroidal neovascular membrane overwhelms the natural pump in the retinal pigment epithelium and subretinal fluid accumulates. The subretinal fluid distorts the retina causing patients to see things as wavy instead of straight. It also decreases the supply of oxygen and nutrients to the retina and makes the vision blurry. Subretinal fluid is best dectected using optical coherence tomography. The photo shows a dark area under the retina where subretinal fluid has accumulated. The effect (or lack of effect) of treatments for wet macular degeneration is usually evaluated by monitoring the optical coherence tomography scan for subretinal fluid.

What is a Pigment Epithelial Detachment?

Most patients with wet AMD develop a retinal pigment epithelial detachment. The retinal pigment epithelium is a layer of cells under the retina that supports the retina. In the OCT image it is the bright white line closest to the bottom of the picture with RPE on top of it. (there are two lines, the line on the bottom is the RPE, the line on the top is the back of the retina). When fluid or lipid (fatty material) or blood vessels accumulates under the retinal pigment epithelium the retinal pigment epithelium is pushed up. The bump in the retinal pigment epithelium is called a pigment epithelial detachment. These are common in wet AMD. Treatment does not always cause the retinal pigment epithelial detachment to flatten. Vision can be excellent over a retinal pigment epithelial detachment. The distortion of the overlying retina will often cause distortion in the vision. Retinal pigment epithlial detachments do not compromise the ability of the retinal pigment epithelium to nurish the retina. Finally, you can develop a retinal pigment epithelial detachment without wet AMD. These retinal pigment epithelial detachments have lipid (fatty) material in them but no blood vessels. About 90 percent of retinal pigment epithelial detachments are associated with wet AMD and abnormal blood vessel growth.

What is a Polypoidal Choroidal Vasculopathy (PCV)?

Polypoidal choroidal vasculopathy is a subtype of wet AMD that is caused by a mature vascular complex under the retina. It is characterized by a branching vascular network with one or more polyps at the termini of the vessels. The branching vascular network and the polyp(s) are best seen with indocyanine green angiography. There is some evidence the polypoidal choroidal vasculaopathy (PCV) is less response to anti-VEGF injection therapy than other forms of wet AMD. In many cases photodynamic therapy is helpful in treating PCV.

What is a Submacular Hemorrhage (Blood)?

Submacular hemorrhage (blood) is one of the most feared complications of wet AMD. The blood is toxic to the overlying retina and causes immediate severe vision loss. The photo shows blood in a patient whose vision dropped from 20/30 immediately to 20/1600 (no longer able to see even the big letters on the visual acuity chart). Fortunately, submacular hemorrhage is rare and occurs in only about 1 percent of patient with wet AMD. Once there is a submacular hemorrhage, vision almost never returns to what it was before the bleed. Treatment of wet AMD helps reduce the amount of vision loss. Surgery for submacular hemorrhage is controversial and may not be helpful. Visual recovery in someone with a submacular hemorrhage is very very slow. It usually takes about 6 months for the blood to absorb and then another 6-12 months for the overlying retina to heal. Vision usually improves some as the blood absorbs but not much. Most patients recover enough vision to see the big letters on the visual acuity chart but not enough vision to read.

Wet Macular Degeneration NEWS

Below are current articles from a Google News Feed on Wet Macular Degeneration

What you need to know about wet macular degeneration  Medical Xpress

Millions of people deal with age-related macular degeneration as they get older, but many don't understand the difference between types of the condition or ...

Gene therapy first to 'halt' most common cause of blindness  BBC News

A woman from Oxford has become the first person in the world to have gene therapy to try to halt the most common form of blindness in the Western world.

Mayo Clinic minute: What you need to know about wet macular degeneration  Sioux City Journal

Millions of people deal with age-related macular degeneration as they get older, but many don't understand the difference between types of the condition or ...

Wet Macular Degeneration Epidemiology Global Insights and Research 2019 to 2028  Nevada Green Times

Delve Insight's “Wet Macular Degeneration – Epidemiology Forecast, 2028 report provides a comprehensive analysis of the Wet Macular Degeneration ...

Wet Macular Degeneration Pipeline Insights, 2019 - ResearchAndMarkets.com  Business Wire

DUBLIN--(BUSINESS WIRE)--The "Wet Macular Degeneration - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Aged-related macular degeneration is incurable but preventable  New Jersey 101.5 FM Radio

Aged-related macular degeneration is the top cause of blindness in people age 50 and older.

Novel anti-VEGF for wet AMD meets safety, tolerability endpoint  Healio

WAIKOLOA, Hawaii — Sunitinib, a novel intravitreal anti-VEGF delivered via a biodegradable depot for extended treatment of neovascular age-related macular ...

Be aware of age-related macular degeneration  thebellvillestar.com

COLUMBUS — Age-related macular degeneration (AMD), is a leading cause of vision loss for Americans age 50 and older. The eye disease causes damage to.

Dr. Kumar-Singh Presents: Anti-Complement Gene Therapy for Dry and Wet AMD: Research Lecture Series  New England College of Optometry

Feb. 19, 2019, 5:00 - 6:00 PM | New England College of Optometry, LH-2. Please join Dr. Kumar-Singh, Tufts University, as he presents, “Anti-Complement Gene ...

Days of our Lives Star Deidre Hall Wants to Help Prevent Blindness from Wet AMD  Parade

Deidre Hall isn't really a doctor; she just plays one on TV. But now the actress, who has played Dr. Marlena Evans on Days of our Lives since 1976, is speaking ...

VIDEO: Visual acuity unchanged after macular hole closure in patients with wet AMD  Healio

WAIKOLOA, Hawaii — There was no statistically significant difference in visual acuity results in patients with wet age-related macular degeneration and ...

Fresh insights into genes and macular degeneration could open new treatment pathways  FierceBiotech

The National Institutes of Health's National Eye Institute (NEI) has been actively searching for new ways to exploit the genetic underpinnings of age-related ...

Are You at Risk for Macular Degeneration? | Health & Wellness  Cape May County Herald

If you're over 65 and of European descent, you could be at risk for macular degeneration, the leading cause of age-related vision loss.

Number of anti-VEGF injections does not affect rate of macular hole development  Healio

WAIKOLOA, Hawaii — The number of anti-VEGF injections given to patients with neovascular age-related macular degeneration did not appear to increase the ...

Wet Macular Degeneration – Market Insight, Epidemiology and Market Forecast – 2028 in Ophthalmology Therapeutic Area  RISReport

Report Titled “Wet Macular Degeneration – Market Insight, Epidemiology and Market Forecast – 2028”. The provides a detailed analysis of the Wet Macular ...

5 Ways to Keep Your Eyes Healthy Every Day  Parade

As we age, our eyes age too, and the risk of eye diseases and conditions— many with no warning signs—climbs.That's why experts stress the importance of an ...

Graybug Vision Presents Top Line Results of Phase 1/2a ADAGIO Study at Hawaiian Eye & Retina 2019  Associated Press

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jan 21, 2019--Graybug Vision, Inc., a clinical stage pharmaceutical company developing potentially transformative ...

Symptom, Visual Outcomes Similar for Both Aflibercept, Ranibizumab  MD Magazine

Patients administered either anti-VEGF therapy for nAMD tested similar for improved visual acuity over an observed 12-month treatment period.

My Turn: 'Twilight Zone' of macular degeneration  Newsday

People have asked me to write a memoir about losing my eyesight. It is not a subject that I am enthralled to write about, but for those who may benefit from my ...

Gene therapies in development for monogenic, complex retinal diseases  Healio

WAIKOLOA, Hawaii — Gene therapy for retinal disease is in various stages of development, with more than a dozen retinal clinical trials underway, Elias Reichel ...

Global 2019 Wet Macular Degeneration Market API Manufacturers, Marketed and Phase III Drugs Landscape  TOP Tribune

Target Audience of “Wet Macular Degeneration Market” Report 2019: Manufacturer / Potential Investors, Traders, Distributors, Wholesalers, Retailers, Importers ...

Global Wet Macular Degeneration – Pipeline Insight, 2018 in Ophthalmology  Thе Prеss Rеvіеwеr

Report Titled “Wet Macular Degeneration – Pipeline Insight, 2018” provides product and API manufacturers' details across the globe along with the location.

2019-2025 Wet Macular Degeneration Market Key strengths, Detailed Overview, Scope, Trends and Industry Analysis Research Report  reportsherald.com

Global Wet Macular Degeneration Market – Epidemiology Forecast to 2028 report delivers an in-depth understanding of the disease, historical & forecasted ...

Interview: Deidre Hall's Mother's Vision Loss Draws Awareness to Wet AMD  Soaps

Hall's mindful advice could save your eyesight. There's a reason Deidre Hall (Dr. Marlena Evans, Hattie Adams) is still a fan favorite after more than 40 years on ...

Fewer Injections With New Wet Macular Degeneration Therapies  Medscape

New treatments in development — including gene therapy — will likely mean fewer injections for patients with neovascular age-related macular degeneration, ...

Global Wet Macular Degeneration market , Detailed Overview, Scope, Trends and Industry Analysis Research Report  reportsherald.com

Global Wet Macular Degeneration Market – Epidemiology Forecast to 2028 report delivers an in-depth understanding of the disease, historical & forecasted ...

What Seniors Need to Know About Vision Loss  U.S. News & World Report

For most of us, hitting age 40 signals a time of change with regard to several aspects of our health. One of the most noticeable is a change in how we see ...

Outlook Therapeutics Announces Exercise Price Reduction and Term Extension of Series A Warrants  Nasdaq

CRANBURY, N.J., Jan. 22, 2019-- Outlook Therapeutics, Inc. today announced that its publicly traded Series A warrants have been amended to lower the.

Age-Related Macular Degeneration: 5 Things to Know  Medscape

A guide to the latest on this chronic disease, from emerging treatments to the risk factors to be on the lookout for.

FDA Approves Aflibercept sBLA for Wet Age-related Macular Degeneration  MD Magazine

A modified 12-week dosing schedule is now available for physicians administering the vascular endothelial growth factor (VEGF) inhibitor to patients with wet ...

7 Top Gainers In Healthcare Sector (IVC, OTLK, MDGL...)  Markets Insider

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector. 1. Invacare Corporation (IVC). Invacare is a manufacturer of medical ...

Avid Bioservices Inc. (CDMOP)'s Financial Results Comparing With TRACON Pharmaceuticals Inc. (NASDAQ:TCON)  The Hi New Ulm

We are comparing Avid Bioservices Inc. (NASDAQ:CDMOP) and TRACON Pharmaceuticals Inc. (NASDAQ:TCON) on their analyst recommendations, ...

Comparing of Atara Biotherapeutics Inc. (ATRA) and Kodiak Sciences Inc. (NASDAQ:KOD)  The Hi New Ulm

As Biotechnology companies, Atara Biotherapeutics Inc. (NASDAQ:ATRA) and Kodiak Sciences Inc. (NASDAQ:KOD) are our subject to compare. And more ...

Graybug Vision Appoints Frédéric Guerard as Chief Executive Officer  Associated Press

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Feb 5, 2019--Graybug Vision, Inc., a clinical stage pharmaceutical company developing potentially transformative ...

Reviewing Ophthotech Corporation (OPHT)'s and NantKwest Inc. (NASDAQ:NK)'s results  The Hi New Ulm

This is therefore a comparing of the dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation in Ophthotech.

(2019-2021) Global Wet Macular Degeneration API Manufacturers, Marketed and Phase III Drugs Landscape  RISReport

2019 Latest Report Titled on: “Wet Macular Degeneration- Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019“. Wet Macular ...

VIDEO: Notal Vision pursues home-based OCT for wet AMD monitoring  Healio

CHICAGO — At the Ophthalmology Innovation Summit at AAO, Quinton Oswald, CEO of Notal Vision, discusses the company's pursuit of an OCT home ...

Nomura Asset Management Company LTD Has Cut Its United Therapeutics Del (UTHR) Holding; Ophthotech (OPHT) Shorts Down By 2.12%  The Hi New Ulm

Nomura Asset Management Company Ltd decreased United Therapeutics Corp Del (UTHR) stake by 55.84% reported in 2018Q3 SEC filing. Nomura Asset ...

EPS for Clearside Biomedical, Inc. (CLSD) Expected At $-0.56 | Thorold News  Thorold News

Analysts expect Clearside Biomedical, Inc. (NASDAQ:CLSD) to report $-0.56 EPS on March, 13.They anticipate $0.09 EPS change or 13.85 % from last quarter's ...

RGX-314 Gene Therapy for Wet AMD Well Tolerated at 24 Weeks  MD Magazine

After a single dose of RGX gene therapy, the mean change in BCVA was +8 letters in cohort 3 and the average number of injections over the course of 6 months ...

Regeneron (REGN) to Report Q4 Earnings: Is a Beat in Store?  Zacks.com

Strong Eylea and Dupixent sales are likely to propel better-than-expected results for Regeneron (REGN) when it reports fourth-quarter results.

Patients with Concurrent Cataracts, Wet AMD Safe to Undergo Cataract Surgery  MD Magazine

Most patients, whether or not they had preoperative fluid, saw improved BCVA post-surgery, and there were no significant differences in central subfield ...

Implantable Ranibizumab Port for Wet AMD Lasts Up to 15 Months  MD Magazine

In a phase 2 study, a long-acting, implantable delivery system for ranibizumab allowed patients with wet age-related macular degeneration to go up to 15 ...

Computers Found to Equal Humans in Diagnosing Age-Related Macular Degeneration  MD Magazine

Computers can do as well as clinicians in diagnosing age-related macular degeneration, say investigators who have developed tools based on artificial ...

Outlook Therapeutics Closes Final Tranche of $20 Million Private Placement  Nasdaq

CRANBURY, N.J., Feb. 01, 2019-- Outlook Therapeutics, Inc. today announced that it closed on the final tranche of its $20.0 million private.

How to spot age-related macular degeneration  The Guardian

Every day in the UK, nearly 200 people develop a condition that can lead to visual impairment or even blindness. How do you identify the symptoms and what's ...

Macular Degeneration Patient Visual Hallucinations Associated with Retina  MD Magazine

The effects of Charles Bonnet Syndrome have been fairly documented, yet its pathology has been minimally assessed.

Revolutionary eye drops to treat age-related macular degeneration  Drug Target Review

Revolutionary eye drops to treat age-related macular degeneration - developing an eye drop that could revolutionise treatment for AMD.

Researchers are one step closer to developing eye drops to treat age-related macular degeneration  Medical Xpress

Scientists at the University of Birmingham are one step closer to developing an eye drop that could revolutionise treatment for age-related macular degeneration ...

Implant Poised to Transform Macular Degeneration Treatment  Medscape

A system that delivers ranibizumab without injections could be a turning point for patients with neovascular age-related macular degeneration, results from the ...

TRACON Pharmaceuticals Announces Positive Data from Ongoing Phase 1b/2 Trial of TRC105 in Hepatocellular Carcinoma  GlobeNewswire

Three Confirmed Partial Responses (20%) by RECIST and > 50% Reductions of Alpha Fetoprotein in Half of Patients Treated to Date with Combination of ...

AMD Monitoring Comes Home: The Promise of Remote Tech  Medscape

Age-related macular degeneration (AMD) is the leading cause of severe vision loss in older Americans. AMD is a degenerative disease that affects the macula, ...

Age-Related Macular Degeneration Drug Combo Scrapped Despite Safe Profile  Specialty Pharmacy Times

Ophthotech Corp. said it won't move forward with further clinical trials of its complement factor C5 inhibitor for the treatment of wet age-related macular ...

5 questions: Breakthroughs in treatment for a common cause of vision loss among US seniors  Philly.com

The standard treatment has been regular injections to the eyeball. So, not surprisingly, an active area of research has focused on finding alternatives, including ...

Kodiak Sciences Inc. (KOD)'s Financial Results Comparing With OPKO Health Inc. (NASDAQ:OPK) | The  The Moveefy

Since Kodiak Sciences Inc. (NASDAQ:KOD) and OPKO Health Inc. (NASDAQ:OPK) are part of the Biotechnology industry, they are influenced by contrast. The.

Opthea Confirms Final Patient Enrolment in Phase 2b Wet AMD Clinical Trial  Associated Press

MELBOURNE, Australia, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel ...

Roche's Faricimab Shows Long-Term Durability in Macular Degeneration  BioSpace

Roche announced positive data from its Phase II STAIRWAY clinical trial. The trial evaluated the extended durability of faricimab (RG7716) in the treatment of ...

VIDEO: Abicipar yields positive results for long-term wet AMD treatment  Healio

CHICAGO ― At the American Academy of Ophthalmology meeting here, Rahul N. Khurana, MD, discusses results from the phase 3 study of abicipar for the ...

Blindness: Macular Degeneration Implant Treatment  Healthline

Researchers say the implant process could eventually be a treatment for the loss of eyesight experienced by millions as they grow older.

Reviewing Ophthotech Corporation (OPHT)'s and Regulus Therapeutics Inc. (:)'s results  The Moveefy

Ophthotech Corporation (NASDAQ:OPHT) and Regulus Therapeutics Inc. (:), both competing one another are Biotechnology companies. We will compare their ...

Drug Pipeline for Macular Degeneration in Focus at AAO  Medscape

Updates from phase 3 trials of VEGF inhibitors for neovascular age-related macular degeneration, and a novel genetic treatment, will be highlighted at the ...

Regenxbio completes dosing in phase 1 trial of gene therapy for wet AMD  Healio

Dosing is complete in a phase 1 clinical trial of RGX-314, a gene therapy treatment for wet age-related macular degeneration, according to a press release from ...

Insomnia Linked to Increased Risk of Developing AMD  MD Magazine

A population-based cohort study identified that patients with insomnia developed AMD at a rate 0.7% higher than those who did not.

Ask the Expert: Macular degeneration can lead to difficulty reading, recognizing faces and performing other fine tasks  Baltimore Sun

Macular degeneration is a disease of the eye that doesn't lead to total blindness, but in its advanced stages can cause blind areas. This can make it hard for ...

Patient Voices: Macular Degeneration  New York Times

Five men and women speak about their lives with progressive vision loss.

Port Delivery System Proves Effective for Patients with Wet AMD in LADDER Trial  MD Magazine

After 6 months, 80% of those implanted with the 100 mg/mL dose of ranibizumab still did not need a medication refill.

Hope for new treatments buoys macular degeneration patients  The Boston Globe

Scientists are experimenting with dozens of new treatments, including about 20 in clinical trials, to combat an eye disease that afflicts more than 9 million ...

First patient dosed in Adverum wet AMD gene therapy trial  Healio

The first patient has been dosed in a phase 1 trial of ADVM-022 gene therapy for wet age-related macular degeneration, Adverum Biotechnologies announced ...

Wills Eye Hospital releases new implant to help macular degeneration  KYW Newsradio 1060

PHILADELPHIA (KYW Newsradio) — There may soon be a way to preserve your vision with a lot less hassle.

Allergan's Big Win For 12-Week Wet AMD Dosing With Abicipar May Be Enough To Pit It Against A Host Of Competitors  Seeking Alpha

Allergan and Molecular Partners achieve positive results in two phase 3 studies using abicipar for treating patients with wet age-related macular degeneration.

Macular Degeneration: Stem Cells Restore Sight in Small Study  Medscape

Doctors in the UK say they have taken an important step towards treating a common form of blindness – wet age-related macular degeneration (AMD).

Reviewing OncoSec Medical Incorporated (ONCS)'s and Clearside Biomedical Inc. (NASDAQ:CLSD)'s results  EN Digest

We will be contrasting the differences between OncoSec Medical Incorporated (NASDAQ:ONCS) and Clearside Biomedical Inc. (NASDAQ:CLSD) as far as ...

Adverum Biotechnologies receives fast track designation for wet AMD therapy  Healio

The FDA granted fast track designation for ADVM-022, a novel gene therapy candidate for the treatment of wet age-related macular degeneration, according to a ...

Don't let macular degeneration get in the way of your life  The Grand Junction Daily Sentinel

It's a dewy morning in the forest as you and your partner make your way through the weekend hike. You're enjoying the sounds of nature but having trouble ...

Stem cells treat macular degeneration  Medical Xpress

In July 2015, 86-year-old Douglas Waters developed severe age-related macular degeneration (AMD). He struggled to see things clearly, even when up close.

Tonix Pharmaceuticals Holding Corp. (TNXP)'s Financial Results Comparing With Clearside Biomedical Inc. (NASDAQ:CLSD)  The FinHeadLines

This is therefore a comparing of the dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership in Tonix.

TRACON Pharmaceuticals Inc (NASDAQ:TCON) Shares Bought by Renaissance Technologies LLC  Fairfield Current

Renaissance Technologies LLC increased its position in TRACON Pharmaceuticals Inc (NASDAQ:TCON) by 12.3% in the 3rd quarter, according to its most ...

Treat-Extend-Stop Protocol for Wet AMD: Long-term Outcomes  Medscape

A retrospective study finds that a treat-extend-stop protocol using anti-VEGF agents for neovascular age-related macular degeneration is associated with ...

NHS Wins High Court Case Over Avastin for Wet AMD  Medscape

NHS CCGs in the north east of England have fought off a High Court challenge to the prescribing of bevacizumab (Avastin) for wet age-related macular ...

Zimura-Lucentis combination safe in wet AMD patients in phase 2a trial  Healio

Zimura, a complement factor C5 inhibitor, was found to be well tolerated in combination with Lucentis in a phase 2a clinical trial, Ophthotech announced in a ...

Tiny eye device could make big difference for millions with blinding disease  Philly.com

Wills Eye Hospital has helped test an implantable delivery system for a widely used medication for age-related macular degeneration.

A Report On Growing Age Related Macular Degeneration (AMD) Market By Wet and Dry Eye, Age, Treatment and Top Players - Global Forecast 2018-2023 |  Medgadget

Global Age Related Macular Degeneration Market report examines the market position and viewpoint of the market globally, from various angles, such as key.

Potential New Drug Target for Age-Related Macular Degeneration Identified  MD Magazine

Those with the AMD showed greater expression of miRNA-150 than those without, offering evidence that miRNA-150 could be used as a potential ...

Reviewing Clearside Biomedical Inc. (CLSD)'s and Arbutus Biopharma Corporation (NASDAQ:ABUS)'s results  The FinHeadLines

Clearside Biomedical Inc. (NASDAQ:CLSD) and Arbutus Biopharma Corporation (NASDAQ:ABUS) compete with each other in the Biotechnology sector. We will ...

Read the bottom line: Eye doctors, Independent Health clash over drug costs  Buffalo News

Retina specialists are seeing red after a major health insurer told them they could be penalized next year if they too often use $2000-a-dose brand name drugs ...

RegenXBio Gene Therapy Shows Early Promise For Eye Disease; Cholesterol Treatment Results Mixed  Forbes

A gene therapy being developed by RegenX Bio of Rockville, MD, showed early promise against wet macular degeneration, a leading cause of blindness.

Adverum Announces First Patient Dosed in OPTIC Phase 1 Trial of ADVM-022 Gene Therapy in Wet Age-Related Macular Degeneration  GlobeNewswire

ADVM-022 is the first intravitreally delivered gene therapy utilizing directed evolution AAV.7m8 vector for wet AMD; OPTIC trial to evaluate single administration ...

Applied Genetic Technologies Corporation (AGTC)'s Financial Results Comparing With Ophthotech Corporation (NASDAQ:OPHT)  The FinHeadLines

This is a contrast between Applied Genetic Technologies Corporation (NASDAQ:AGTC) and Ophthotech Corporation (NASDAQ:OPHT) based on their ...

Reviewing Kindred Biosciences Inc. (KIN)'s and Kodiak Sciences Inc. (NASDAQ:KOD)'s results  EN Digest

Kindred Biosciences Inc. (NASDAQ:KIN) and Kodiak Sciences Inc. (NASDAQ:KOD) compete against each other in the Biotechnology sector. We will compare ...

Novartis challenges court ruling allowing use of Avastin in wet AMD  pharmaphorum

Novartis is appealing against a High Court ruling that it is lawful for the NHS to prescribe Roche's Avastin in an unlicensed use in wet AMD.

Regeneron's Eylea Gets FDA Nod for Wet AMD as a 12-Week Dose  Nasdaq

Regeneron Pharmaceuticals, Inc. REGN announced that the FDA has approved a supplemental Biologics License Application (sBLA) for its flagship.

Mediterranean Diet and Macular Degeneration  Healthline

A recent study published in the journal Ophthalmology found that following a Mediterranean diet might help reduce the risk of developing macular degeneration.

Eye implant could more effectively prevent a common form of blindness  New Atlas

Age-related macular degeneration (AMD) is one of the leading causes of blindness in older people, with the "wet" form of the disease being responsible for ...

Macular degeneration: 'I've been given my sight back'  BBC News

Doctors have taken a major step towards curing the most common form of blindness in the UK - age-related macular degeneration. Douglas Waters, 86, could ...

Fewer doses of abicipar yield similar efficacy as ranibizumab for wet AMD  Healio

The anti-VEGF abicipar pegol was similarly efficacious in treating neovascular age-related macular degeneration as ranibizumab, meeting the primary endpoint ...

Comparing of Ophthotech Corporation (OPHT) and NovaBay Pharmaceuticals Inc. (NYSEAMERICAN:NBY)  The FinReviewer

Ophthotech Corporation (NASDAQ:OPHT) and NovaBay Pharmaceuticals Inc. (NYSEAMERICAN:NBY) compete against each other in the Biotechnology sector.

A Daily Orange May Reduce AMD Risk, Study Finds  Medscape

People who consume at least one orange per day have a 60% lower risk of developing age-related macular degeneration (AMD) 15 years later compared with ...

Stem Cells Show Promise For Macular Degeneration  WebMD

A new stem cell transplant might help preserve or even restore vision being lost to the dry form of age-related macular degeneration.

Malaria Drug Amodiaquine Improves Blood Vessel Growth in AMD  MD Magazine

In animal models, not only did the drug help protect apelin function-deficient models from laser-induced choroidal neovascularization, but it did it through unique ...

Implanting stem cell 'patch' can restore vision  Futurity: Research News

Clinical trial results show that a stem cell patch can treat sudden, severe sight loss due to a form of macular degeneration.

» Load more

What about Resources?

Dr. Pautler's Blog
American Academy of Ophthalmology
MedlinePlus
National Institutes of Health
  • ARMD
    NIH's SeniorHealth website covers the topic of Age-Related Macular Degeneration
National Eye Institute
American Foundation for the Blind - Senior Site
  • Macular Degeneration
    Basic information about AMD and low vision; includes a self-test using an Amsler Grid
Journal of the American Medical Association (JAMA)
WebMD
LightHouse International
  • Macular Degeneration
    Provides a general overview of the basics of AMD, and a simulation showing a scene as it might be viewed by a person with AMD
Prevent Blindness America